Retagliptin
- Generic Name
- Retagliptin
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F6N4O3
- CAS Number
- 1174122-54-3
- Unique Ingredient Identifier
- 328C4R3P9L
- Background
Retagliptin is under investigation in clinical trial NCT02822534 (The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients).
- Indication
用于改善成人2型糖尿病患者的血糖控制。
①单药：本品单药可配合饮食控制和运动，改善成人2型糖尿病患者的血糖控制。
②与盐酸二甲双胍联合使用：在单独使用盐酸二甲双胍血糖控制不佳时，本品可与盐酸二甲双胍联合使用，配合饮食和运动改善成人2型糖尿病患者的血糖控制。
SP2086 Pharmacokinetic Study in Renal Insufficiency Patients
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02815774
The Drug-drug Interaction of SP2086 and Simvastatin
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02815722
- Locations
- 🇨🇳
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, China
The Drug-drug Interaction of SP2086 and Metformin
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02813863
Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01984489
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath